Moreover, the OS for pancreatic cancer patients with higher TCF7L2 expression was significantly shorter than for patients with low TCF7L2 expression (P < 0.001, median survival time: 33.6 months vs. 17.1 months vs. 10.5 months vs. 6.2 months). The gene discussed is TCF7L2; the disease is pancreatic neoplasm.